First Trust Direct Indexing L.P. Takes $252,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

First Trust Direct Indexing L.P. bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,385 shares of the company’s stock, valued at approximately $252,000.

Other hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after acquiring an additional 7,537 shares during the last quarter. Hood River Capital Management LLC grew its position in Krystal Biotech by 5.1% during the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after acquiring an additional 25,507 shares during the period. Bank of New York Mellon Corp increased its stake in Krystal Biotech by 115.7% during the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after acquiring an additional 103,928 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Krystal Biotech by 11.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company’s stock worth $32,402,000 after purchasing an additional 18,021 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 14.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on KRYS shares. Stifel Nicolaus increased their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Evercore ISI upped their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Citigroup reissued a “neutral” rating and issued a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Finally, Chardan Capital boosted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus price target of $196.75.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $170.85 on Tuesday. The firm has a 50-day moving average of $182.28 and a two-hundred day moving average of $180.12. The stock has a market cap of $4.91 billion, a P/E ratio of 46.81 and a beta of 0.82. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same quarter in the prior year, the business posted ($1.25) earnings per share. Krystal Biotech’s revenue for the quarter was up 70283900.0% on a year-over-year basis. As a group, equities analysts expect that Krystal Biotech, Inc. will post 2.88 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).